Literature DB >> 28871512

Decision Making and Priority Setting: The Evolving Path Towards Universal Health Coverage.

Francesco Paolucci1,2, Ken Redekop3,4, Ayman Fouda5,6, Gianluca Fiorentini2.   

Abstract

Health technology assessment (HTA) is widely viewed as an essential component in good universal health coverage (UHC) decision-making in any country. Various HTA tools and metrics have been developed and refined over the years, including systematic literature reviews (Cochrane), economic modelling, and cost-effectiveness ratios and acceptability curves. However, while the cost-effectiveness ratio is faithfully reported in most full economic evaluations, it is viewed by many as an insufficient basis for reimbursement decisions. Emotional debates about the reimbursement of cancer drugs, orphan drugs, and end-of-life treatments have revealed fundamental disagreements about what should and should not be considered in reimbursement decisions. Part of this disagreement seems related to the equity-efficiency tradeoff, which reflects fundamental differences in priorities. All in all, it is clear that countries aiming to improve UHC policies will have to go beyond the capacity building needed to utilize the available HTA toolbox. Multi-criteria decision analysis (MCDA) offers a more comprehensive tool for reimbursement decisions where different weights of different factors/attributes can give policymakers important insights to consider. Sooner or later, every country will have to develop their own way to carefully combine the results of those tools with their own priorities. In the end, all policymaking is based on a mix of facts and values.

Entities:  

Mesh:

Year:  2017        PMID: 28871512     DOI: 10.1007/s40258-017-0349-3

Source DB:  PubMed          Journal:  Appl Health Econ Health Policy        ISSN: 1175-5652            Impact factor:   2.561


  4 in total

1.  Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion.

Authors:  Andreja Detiček; Andrej Janzic; Igor Locatelli; Mitja Kos
Journal:  BMC Health Serv Res       Date:  2018-06-27       Impact factor: 2.655

2.  Factors Affecting Usage Levels and Trends of Innovative Oncology Drugs Upon and After Reimbursement Under Taiwan National Health Insurance: Interrupted Time Series Analysis.

Authors:  Kai-Hsin Liao; Bor-Sheng Ko; Liang-Kung Chen; Fei-Yuan Hsiao
Journal:  Clin Transl Sci       Date:  2020-07-16       Impact factor: 4.689

3.  A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).

Authors:  Fernando de Andrés-Nogales; Encarnación Cruz; Miguel Ángel Calleja; Olga Delgado; Maria Queralt Gorgas; Jaime Espín; Jorge Mestre-Ferrándiz; Francesc Palau; Alba Ancochea; Rosabel Arce; Raquel Domínguez-Hernández; Miguel Ángel Casado
Journal:  Orphanet J Rare Dis       Date:  2021-04-26       Impact factor: 4.123

Review 4.  The sociology of rationing: Towards increased interdisciplinary dialogue - A critical interpretive literature review.

Authors:  Amalie Martinus Hauge; Eva Iris Otto; Sarah Wadmann
Journal:  Sociol Health Illn       Date:  2022-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.